Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 8
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
PD-L1 expression
gastric cancer · Small Molecule Inhibitor
PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 14 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 18
Common snippets: dMMR | dMMR | dMMR
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT06152523 | https://clinicaltrials.gov/study/NCT05218148 | https://clinicaltrials.gov/study/NCT07511894 | https://clinicaltrials.gov/study/NCT07621562 | https://clinicaltrials.gov/study/NCT07692334 | https://clinicaltrials.gov/study/NCT07259473 | https://clinicaltrials.gov/study/NCT05933980 | https://clinicaltrials.gov/study/NCT06346197 | https://clinicaltrials.gov/study/NCT07674342 | https://clinicaltrials.gov/study/NCT05572684 | https://clinicaltrials.gov/study/NCT06580574 | https://clinicaltrials.gov/study/NCT05832892 | https://clinicaltrials.gov/study/NCT06222944 | https://clinicaltrials.gov/study/NCT06093425